Financhill
Back

Blueprint Medicines Stock Price Chart

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BPMC is experiencing selling pressure, which indicates risk of future bearish movement.

Blueprint Medicines Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 89.39 Buy
20-day SMA: 91.05 Sell
50-day SMA: 98.95 Sell
200-day SMA: 97.56 Sell
8-day EMA: 90.15 Sell
20-day EMA: 92.43 Sell
50-day EMA: 95.69 Sell
200-day EMA: 94.28 Sell

Blueprint Medicines Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): -2.89 Sell
Relative Strength Index (14 RSI): 42.61 Sell
Chaikin Money Flow: -715786 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (88.16 - 98.26) Sell
Bollinger Bands (100): (87.24 - 104.2) Sell

Blueprint Medicines Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Blueprint Medicines Stock

Is Blueprint Medicines Stock a Buy?

BPMC Technical Analysis vs Fundamental Analysis

Sell
45
Blueprint Medicines (BPMC) is a Sell

Is Blueprint Medicines a Buy or a Sell?

Blueprint Medicines Stock Info

Market Cap:
5.7B
Price in USD:
89.59
Share Volume:
810.1K

Blueprint Medicines 52-Week Range

52-Week High:
121.90
52-Week Low:
80.68
Sell
45
Blueprint Medicines (BPMC) is a Sell

Blueprint Medicines Share Price Forecast

Is Blueprint Medicines Stock a Buy?

  • Blueprint Medicines share price is 89.59 while BPMC 8-day exponential moving average is 90.15, which is a Sell signal.
  • The stock price of BPMC is 89.59 while Blueprint Medicines 20-day EMA is 92.43, which makes it a Sell.
  • Blueprint Medicines 50-day exponential moving average is 95.69 while BPMC share price is 89.59, making it a Sell technically.
  • BPMC stock price is 89.59 and Blueprint Medicines 200-day simple moving average is 94.28, creating a Sell signal.

Fundamental Analysis of Blueprint Medicines

Is Blueprint Medicines a good investment?

  • Analysts estimate an earnings increase this quarter of $0.69 per share, an increase next quarter of $0.00 per share, an increase this year of $0.09 per share, and an increase next year of $2.69 per share.

Technical Analysis of Blueprint Medicines

Should I short Blueprint Medicines stock?

* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.